The Oncotype Dx, MammaPrint, BCI, and EndoPredict are applicable for HR-positive HER-2-negative breast cancer patients at stage N0–N1, while RecurIndex is for HR-positive patients at stage N0–N2. Here, ERBB2 is linked to breast cancer.